Low p27 expression predicts poor disease-free survival in patients with prostate cancer

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 941-945

  Yang, Ronald M ^b   Naitoh, John ^b   Murphy, Michael ^b   Wang, He Jing ^b   Phillipson, Julia ^b   DeKernion, Jean B ^b   Loda, Massimo ^b   Reiter, Robert E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Gene products, rex; Prostatic neoplasms; Tumor markers

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE SECTION;

EID: 0031930822     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63776-5     Document Type: Article

References (16)

1. Koff, A., Cross, F., Fisher, A., Schumacher, J., Leguellec, K., Philippe, M. and Roberts, J. M.: Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell, 66: 1217, 1991.
2. Dulic, V., Lees, E. and Reed, S. I.: Association of human cyclin E with a periodic G1-S phase protein kinase. Science, 257: 1958, 1992.
3. Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M. and Koff, A.: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Gene Dev., 8: 9, 1994.
4. Ferrando, A. A., Balbin, M., Pendas, A. M., Vizoso, F., Velasco, G. and Lopez-Otin, C. F.: Mutational analysis of the human-cyclin dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Hum. Genet., 97: 91, 1996.
5. Coats, S., Flanagan, W. M., Nourse, J. and Roberts, J. M.: Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science, 272: 877, 1996.
6. St Croix, B., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M. and Kerbel, R. S.: Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204, 1996.
7. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I. and Slingerland, J. M.: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227, 1997.
8. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R. and Roberts, J. M.: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat. Med., 3: 222, 1997.
9. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M. and Pagano, M.: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231, 1997.
10. Mori, M., Mimori, K., Shiraishi, T., Tanaka, S., Ueo, H., Sugimachi, K. and Akiyoshi, T.: p27 expression and gastric carcinoma. Nat. Med., 3: 593, 1997.
11. Epstein, J. I., Carmichael, M. and Walsh, P. C.: Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J. Urol., 149: 1040, 1993.
12. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., 152: 1837, 1994.
13. Kupelian, P. A., Katcher, J., Levin, H. S. and Klein, E. A.: Stage T1-2 Prostate Cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int. J. Rad. Oncol., Biol. Phys., 37: 1043, 1997.
14. Lerner, S. E., Blute, M. L. and Zincke, H.: Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Sem. Urol. Oncol., 14: 12, 1996.
15. Steeg, P. S. and Abrams, J. S.: Cancer prognostics: past, present and p27. Nat. Med., 3: 152, 1997.
16. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C., Lairn, P., Draetta, G., Pagano, M. and Loda, M.: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res., 57: 1259, 1997.